162 related articles for article (PubMed ID: 22001094)
1. Discovery of cyclic guanidines as potent, orally active, human glucagon receptor antagonists.
Sinz C; Chang J; Lins AR; Brady E; Candelore M; Dallas-Yang Q; Ding V; Jiang G; Lin Z; Mock S; Qureshi S; Salituro G; Saperstein R; Shang J; Szalkowski D; Tota L; Vincent S; Wright M; Xu S; Yang X; Zhang B; Tata J; Kim R; Parmee E
Bioorg Med Chem Lett; 2011 Dec; 21(23):7131-6. PubMed ID: 22001094
[TBL] [Abstract][Full Text] [Related]
2. Discovery of N-aryl-2-acylindole human glucagon receptor antagonists.
Sinz C; Bittner A; Brady E; Candelore M; Dallas-Yang Q; Ding V; Jiang G; Lin Z; Qureshi S; Salituro G; Saperstein R; Shang J; Szalkowski D; Tota L; Vincent S; Wright M; Xu S; Yang X; Zhang B; Tata J; Kim R; Parmee ER
Bioorg Med Chem Lett; 2011 Dec; 21(23):7124-30. PubMed ID: 22030028
[TBL] [Abstract][Full Text] [Related]
3. New beta-alanine derivatives are orally available glucagon receptor antagonists.
Lau J; Behrens C; Sidelmann UG; Knudsen LB; Lundt B; Sams C; Ynddal L; Brand CL; Pridal L; Ling A; Kiel D; Plewe M; Shi S; Madsen P
J Med Chem; 2007 Jan; 50(1):113-28. PubMed ID: 17201415
[TBL] [Abstract][Full Text] [Related]
4. Discovery of potent, orally active benzimidazole glucagon receptor antagonists.
Kim RM; Chang J; Lins AR; Brady E; Candelore MR; Dallas-Yang Q; Ding V; Dragovic J; Iliff S; Jiang G; Mock S; Qureshi S; Saperstein R; Szalkowski D; Tamvakopoulos C; Tota L; Wright M; Yang X; Tata JR; Chapman K; Zhang BB; Parmee ER
Bioorg Med Chem Lett; 2008 Jul; 18(13):3701-5. PubMed ID: 18539028
[TBL] [Abstract][Full Text] [Related]
5. Discovery of novel, potent, selective, and orally active human glucagon receptor antagonists containing a pyrazole core.
Shen DM; Brady EJ; Candelore MR; Dallas-Yang Q; Ding VD; Feeney WP; Jiang G; McCann ME; Mock S; Qureshi SA; Saperstein R; Shen X; Tong X; Tota LM; Wright MJ; Yang X; Zheng S; Chapman KT; Zhang BB; Tata JR; Parmee ER
Bioorg Med Chem Lett; 2011 Jan; 21(1):76-81. PubMed ID: 21147532
[TBL] [Abstract][Full Text] [Related]
6. Human glucagon receptor antagonists with thiazole cores. A novel series with superior pharmacokinetic properties.
Madsen P; Kodra JT; Behrens C; Nishimura E; Jeppesen CB; Pridal L; Andersen B; Knudsen LB; Valcarce-Aspegren C; Guldbrandt M; Christensen IT; Jørgensen AS; Ynddal L; Brand CL; Bagger MA; Lau J
J Med Chem; 2009 May; 52(9):2989-3000. PubMed ID: 19385613
[TBL] [Abstract][Full Text] [Related]
7. Discovery of furan-2-carbohydrazides as orally active glucagon receptor antagonists.
Hasegawa F; Niidome K; Migihashi C; Murata M; Negoro T; Matsumoto T; Kato K; Fujii A
Bioorg Med Chem Lett; 2014 Sep; 24(17):4266-70. PubMed ID: 25127101
[TBL] [Abstract][Full Text] [Related]
8. The discovery of N-((2H-tetrazol-5-yl)methyl)-4-((R)-1-((5r,8R)-8-(tert-butyl)-3-(3,5-dichlorophenyl)-2-oxo-1,4-diazaspiro[4.5]dec-3-en-1-yl)-4,4-dimethylpentyl)benzamide (SCH 900822): a potent and selective glucagon receptor antagonist.
DeMong D; Dai X; Hwa J; Miller M; Lin SI; Kang L; Stamford A; Greenlee W; Yu W; Wong M; Lavey B; Kozlowski J; Zhou G; Yang DY; Patel B; Soriano A; Zhai Y; Sondey C; Zhang H; Lachowicz J; Grotz D; Cox K; Morrison R; Andreani T; Cao Y; Liang M; Meng T; McNamara P; Wong J; Bradley P; Feng KI; Belani J; Chen P; Dai P; Gauuan J; Lin P; Zhao H
J Med Chem; 2014 Mar; 57(6):2601-10. PubMed ID: 24527772
[TBL] [Abstract][Full Text] [Related]
9. Discovery of novel, potent, and orally active spiro-urea human glucagon receptor antagonists.
Shen DM; Zhang F; Brady EJ; Candelore MR; Dallas-Yang Q; Ding VD; Dragovic J; Feeney WP; Jiang G; McCann PE; Mock S; Qureshi SA; Saperstein R; Shen X; Tamvakopoulos C; Tong X; Tota LM; Wright MJ; Yang X; Zheng S; Chapman KT; Zhang BB; Tata JR; Parmee ER
Bioorg Med Chem Lett; 2005 Oct; 15(20):4564-9. PubMed ID: 16102966
[TBL] [Abstract][Full Text] [Related]
10. Discovery of potent and orally bioavailable indazole-based glucagon receptor antagonists for the treatment of type 2 diabetes.
Xu G; Gaul MD; Song F; Du F; Liang Y; DesJarlais RL; DiLoreto K; Shook B; Rentzeperis D; Santulli R; Eckardt A; Demarest K
Bioorg Med Chem Lett; 2019 Oct; 29(20):126668. PubMed ID: 31519374
[TBL] [Abstract][Full Text] [Related]
11. Hepatic glucagon receptor binding and glucose-lowering in vivo by peptidyl and non-peptidyl glucagon receptor antagonists.
Dallas-Yang Q; Shen X; Strowski M; Brady E; Saperstein R; Gibson RE; Szalkowski D; Qureshi SA; Candelore MR; Fenyk-Melody JE; Parmee ER; Zhang BB; Jiang G
Eur J Pharmacol; 2004 Oct; 501(1-3):225-34. PubMed ID: 15464082
[TBL] [Abstract][Full Text] [Related]
12. Discovery and investigation of a novel class of thiophene-derived antagonists of the human glucagon receptor.
Duffy JL; Kirk BA; Konteatis Z; Campbell EL; Liang R; Brady EJ; Candelore MR; Ding VD; Jiang G; Liu F; Qureshi SA; Saperstein R; Szalkowski D; Tong S; Tota LM; Xie D; Yang X; Zafian P; Zheng S; Chapman KT; Zhang BB; Tata JR
Bioorg Med Chem Lett; 2005 Mar; 15(5):1401-5. PubMed ID: 15713396
[TBL] [Abstract][Full Text] [Related]
13. Discovery of a nortropanol derivative as a potent and orally active GPR119 agonist for type 2 diabetes.
Xia Y; Chackalamannil S; Greenlee WJ; Jayne C; Neustadt B; Stamford A; Vaccaro H; Xu XL; Baker H; O'Neill K; Woods M; Hawes B; Kowalski T
Bioorg Med Chem Lett; 2011 Jun; 21(11):3290-6. PubMed ID: 21536438
[TBL] [Abstract][Full Text] [Related]
14. Discovery of the first potent and orally efficacious agonist of the orphan G-protein coupled receptor 119.
Semple G; Fioravanti B; Pereira G; Calderon I; Uy J; Choi K; Xiong Y; Ren A; Morgan M; Dave V; Thomsen W; Unett DJ; Xing C; Bossie S; Carroll C; Chu ZL; Grottick AJ; Hauser EK; Leonard J; Jones RM
J Med Chem; 2008 Sep; 51(17):5172-5. PubMed ID: 18698756
[TBL] [Abstract][Full Text] [Related]
15. Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus.
Imamura M; Nakanishi K; Suzuki T; Ikegai K; Shiraki R; Ogiyama T; Murakami T; Kurosaki E; Noda A; Kobayashi Y; Yokota M; Koide T; Kosakai K; Ohkura Y; Takeuchi M; Tomiyama H; Ohta M
Bioorg Med Chem; 2012 May; 20(10):3263-79. PubMed ID: 22507206
[TBL] [Abstract][Full Text] [Related]
16. Discovery of liver selective non-steroidal glucocorticoid receptor antagonist as novel antidiabetic agents.
Shah K; Patel D; Jadav P; Sheikh M; Sairam KV; Joharapurkar A; Jain MR; Bahekar R
Bioorg Med Chem Lett; 2012 Sep; 22(18):5857-62. PubMed ID: 22917520
[TBL] [Abstract][Full Text] [Related]
17. A novel series of indazole-/indole-based glucagon receptor antagonists.
Lin S; Zhang F; Jiang G; Qureshi SA; Yang X; Chicchi GG; Tota L; Bansal A; Brady E; Trujillo M; Salituro G; Miller C; Tata JR; Zhang BB; Parmee ER
Bioorg Med Chem Lett; 2015 Oct; 25(19):4143-7. PubMed ID: 26303893
[TBL] [Abstract][Full Text] [Related]
18. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Kim D; Wang L; Beconi M; Eiermann GJ; Fisher MH; He H; Hickey GJ; Kowalchick JE; Leiting B; Lyons K; Marsilio F; McCann ME; Patel RA; Petrov A; Scapin G; Patel SB; Roy RS; Wu JK; Wyvratt MJ; Zhang BB; Zhu L; Thornberry NA; Weber AE
J Med Chem; 2005 Jan; 48(1):141-51. PubMed ID: 15634008
[TBL] [Abstract][Full Text] [Related]
19. A novel series of glucagon receptor antagonists with reduced molecular weight and lipophilicity.
Filipski KJ; Bian J; Ebner DC; Lee EC; Li JC; Sammons MF; Wright SW; Stevens BD; Didiuk MT; Tu M; Perreault C; Brown J; Atkinson K; Tan B; Salatto CT; Litchfield J; Pfefferkorn JA; Guzman-Perez A
Bioorg Med Chem Lett; 2012 Jan; 22(1):415-20. PubMed ID: 22119466
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of novel imidazoline derivatives with potent antihyperglycemic activity in a rat model of type 2 diabetes.
Crane L; Anastassiadou M; El Hage S; Stigliani JL; Baziard-Mouysset G; Payard M; Leger JM; Bizot-Espiard JG; Ktorza A; Caignard DH; Renard P
Bioorg Med Chem; 2006 Nov; 14(22):7419-33. PubMed ID: 16889967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
